Navigation Links
Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives
Date:12/3/2008

vailable via a link in the Investor section at http://investor.sangamo.com/index.cfm under "Events and Presentations".

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs are focused on cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies outside of the human therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform to specific human disease as well as plant agriculture, high value research reagents and cell-line engineering, clinical tria
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
2. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
3. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
4. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
7. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
8. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
11. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Restore Health, a leading personalized medicine company ... it is now offering pharmacogenetics testing that provides ... upon their particular genetic makeup. Comprehensive medication management ... a patient,s genetics and their entire drug regimen.  ... this new service to healthcare providers and their ...
(Date:7/24/2014)... UNION CITY, Calif., July 24, 2014  Abaxis, Inc. ... manufacturing point-of-care blood analysis systems, today reported financial results ... First quarter overview: , Revenues of ... , Diluted EPS of $0.21, up 50% over ... , Medical market revenues of $7.2 million, up 20% ...
(Date:7/24/2014)... 2014 Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... to discuss the Company,s Second Quarter 2014 financial ... earnings conference call and webcastWhen: , July ... chairman, president and chief executive officer ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... , WASHINGTON, Dec. 10 BioWorld Today ... Research and Manufacturers of America ( PhRMA ) that identifies 97 new ... conditions. , The report , which was released ahead of ... found that the 97 products in development include 23 vaccines and 54 ...
... , MILFORD, Mass., Dec. 10 ... that it is partnering with the NC BioNetwork Pharmaceutical ... NC, to educate and train students and workers in ... biopharmaceutical industry. The Pharmaceutical Center, which is a collaborative ...
Cached Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4
(Date:7/27/2014)... Bags underneath the eyes is one condition ... there are a range of new products now available from ... baggy eyes serum review that is now posted for adults ... the issues with baggy eyes and how the natural ingredients ... The guide also provides a detailed overview of the creams ...
(Date:7/27/2014)... The report, “Glass Fiber & ... Raw Material, By Manufacturing Process, By Application (Transportation, ... Geography – Global Trends & Forecast to 2019”, ... with an analysis and forecast by value and ... 107 figures spread through 347 slides and in-depth ...
(Date:7/27/2014)... Prominent Vancouver Chiropractors, Dr. Shervin Ranjbar and ... hamstring release procedure in Vancouver, BC. Both these chiropractors ... and have years of experience in the field of ... by the two professionals using a foam roller exercise. ... release tight hamstrings and relieve the client of the ...
(Date:7/27/2014)... City (Sunday July 27 11:45 am ET): ... at the surgical sitehas been reduced by 77 ... in the American College of Surgeons National Surgical ... new case study presented at the 2014 ACS ... British Columbia, reportedly reduced its rate of cardiac ...
(Date:7/27/2014)... 2014 Metachromatic leukodystrophy (MLD, also ... disease which is commonly listed in the family ... as it affects the metabolism of sphingolipids. Leukodystrophies ... fatty covering which acts as an insulator around ... systems. MLD involves cerebroside sulfate accumulation. Metachromatic leukodystrophy, ...
Breaking Medicine News(10 mins):Health News:Baggy Eyes Serum Review Posted for Men and Women at Cherry News Website 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 2Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 3Health News:Major Drivers for GFRP Composites Market in Future – Report by MarketsandMarkets 4Health News:Renowned Vancouver Chiropractors Demonstrates Hamstring Release in Vancouver, BC 2Health News:Surgical safety program greatly reduces surgical site infections for heart operations 2Health News:Surgical safety program greatly reduces surgical site infections for heart operations 3Health News:Surgical safety program greatly reduces surgical site infections for heart operations 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 2Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 3Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 4Health News:Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com 5
... Hospital today became the first in Ontario to implant a small ... about the size of a Zippo lighter is the ... highest level of energy, 40 joules. The narrow shape ... incision in the patient,s chest, which should mean a faster recovery ...
... , TUESDAY, Dec. 21 (HealthDay News) -- Like ... their sex, say researchers who spent 14 years observing a ... researchers found that both male and female chimpanzee youngsters play ... treat the sticks as would mothers caring for their infants. ...
... , TUESDAY, Dec. 21 (HealthDay News) -- Children ... independent in adulthood, new study findings suggest. For example, ... shoes in the bedroom or apples in the supermarket, according ... Kingdom. The study authors asked 20 children with autism ...
... , HOUSTON, Dec. 21, 2010 The day when an ... painless pill instead of a toxic drug cocktail is the ... Houston (UH) scientist. Preethi Gunaratne, assistant professor in ... of tiny genetic molecules known as microRNAs and pinpointing those ...
... morbidly obese persons face many health issues -- heart disease, ... chances of dying while driving during a severe auto accident ... vehicle crash, a moderately obese driver faces a 21 percent ... 56 percent increased risk of not surviving, according to a ...
... By Jenifer Goodwin HealthDay Reporter , TUESDAY, ... discovered in recent years, losing a job is upsetting and ... But buck up. About a year later, the majority ... returned to their previous levels of happiness, a new study ...
Cached Medicine News:Health News:Young Female Chimps Use Sticks as 'Dolls' 2Health News:UH biochemist works to revolutionize ovarian cancer treatment 2Health News:UH biochemist works to revolutionize ovarian cancer treatment 3Health News:UH biochemist works to revolutionize ovarian cancer treatment 4Health News:Obesity increases risk of death in severe vehicle crashes, study shows 2Health News:Most People Regain Happiness After Job Loss 2Health News:Most People Regain Happiness After Job Loss 3
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
The Erythrocyte Sedimentation Rate (ESR) can be used as a nonspecific search technique in case of suspicion of inflammatory reactions as well as for judgement of their development. VACUETTE ESR tubes...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Glucose tubes contain an anti-coagulant and a stabiliser. The tubes are ideal for glucose and lactate determinations....
Medicine Products: